← Map · Health Care Equipment · S&P SmallCap 600
AORT ARTIVION INC $1.1B
No. The quarter is the aortic arch portfolio.
1 of 15
Reach, Weight, and Proof.
What they are doing
Artivion's year is the aortic arch: Endospan, NEXUS, and FDA approval of AMDS. The 10-K mentions artificial intelligence twice, both as risk. One is that AI platforms make security breaches harder to stop. The other is that privacy, sustainability, and AI rules are multiplying. Neither is a product or an operating use.
Why the score
- Reach 0 not 1: no function on the chain.
- Weight 0 not 1: no experiment in the filing.
- Proof 1 not 0: the 10-K does use the words, as a threat and as regulation.
- Proof 1 not 2: not tied to an operating function.
What would move it next quarter: A named intelligence layer in an aortic product. Another arch approval will not move this.
Open these first
Evidence
Security efforts may not prevent breaches, particularly in light of rapid improvements in information processing technology accompanying developments in artificial intelligence platforms. The company is also subject to a growing set of laws on data privacy, sustainability, and artificial intelligence.